nach oben

Erschienen in:

29.07.2016 | Original Article

Prophylactic efficacy of enteral miconazole administration for neonatal intestinal perforation and its potential mechanism

verfasst von: Motofumi Torikai, Satoshi Ibara, Satoshi Ieiri, Takashi Hamada, Hiroyuki Noguchi, Kazunobu Sueyoshi, Takeo Fukuda, Kazuhiro Abeyama

Erschienen in: Pediatric Surgery International | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Intestinal perforation (IP) is a fatal complication in extremely low birth weight infants (ELBWI). We started administrating enteral miconazole (MCZ) to ELBWI in 2002. Since then, the incidence of IP has significantly decreased. The aim of this study was to elucidate the prophylactic effect of MCZ for the treatment of neonatal IP, and to establish a new prophylactic concept for this disease.

Methods

In in vivo experiments, the effects of MCZ were examined histopathologically using a mouse model of intestinal ischemia. In in vitro experiments, the cytoprotective effect of MCZ against hypoxia was evaluated using Caco-2 intestinal cells, and its anti-inflammatory potential using a co-culture model of Caco-2 and HL60 cells.

Results

MCZ showed a tissue protective effect against intestinal ischemia. MCZ reduced high mobility group-box 1 (HMGB1) release in Caco-2 cells under hypoxic stress and attenuated the potential to activate co-cultured HL60 leukocytes with Caco-2 cells by suppressing interleukin-8 (IL-8).

Conclusion

MCZ may have preventive roles in the clinical management of IP in ELBWI by the suppression of IL-8 and HMGB-1.

Lin PW, Stoll BJ (2006) Necrotising enterocolitis. Lancet 368:1271–1283CrossRefPubMed

Thyoka M, de Coppi P, Eaton S, Khoo K, Hall NJ, Curry J, Kiely E, Drake D, Cross K, Pierro A (2012) Advanced necrotizing enterocolitis part 1: mortality. Eur J Pediatr Surg 22:8–12CrossRefPubMed

Neu J, Chen M, Beierle E (2005) Intestinal innate immunity: how does it relate to the pathogenesis of necrotizing enterocolitis. Semin Pediatr Surg 14:137–144CrossRefPubMed

Anand RJ, Leaphart CL, Mollen KP et al (2007) The role of the intestinal barrier in the pathogenesis of necrotizing enterocolitis. Shock 27:124–133CrossRefPubMed

Martin CR, Walker WA (2006) Intestinal immune defences and the inflammatory response in necrotising enterocolitis. Semin Fetal Neonatal Med 11:369–377CrossRefPubMed

Nanthakumar NN, Fusunyan RD, Sanderson I et al (2000) Inflammation in the developing human intestine: a possible pathophysiologic contribution to necrotizing enterocolitis. Proc Natl Acad Sci USA 97:6043–6048CrossRefPubMedPubMedCentral

Abeyama K, Kawahara K, Iino S et al (2003) Antibiotic cyclic AMP signaling by “primed” leukocytes confers anti-inflammatory cytoprotection. J Leukoc Biol 74:908–915CrossRefPubMed

Lalla RV, Bensadoun RJ (2011) Miconazole mucoadhesive tablet for oropharyngeal candidiasis. Expert Rev Anti Infect Ther 9:13–17CrossRefPubMedPubMedCentral

Naoko Kanda UE, Watanabe S (2001) Anti-Mycotics Suppress Interleukin-4 and Interleukin-5 Production in Anti-CD3 Plus Anti-CD28-Stimulated T Cells from Patients with Atopic Dermatitis. J Invest Dermatol 117:1635–1646CrossRef

10.

Wu CH, Jeng JH, Wang YJ et al (2002) Antitumor effects of miconazole on human colon carcinoma xenografts in nude mice through induction of apoptosis and G0/G1 cell cycle arrest. Toxicol Appl Pharmacol 180:22–35CrossRefPubMed

11.

Maede Y, Ibara S, Nagasaki H et al (2013) Micafungin versus fluconazole for prophylaxis against fungal infections in premature infants. Pediatr Int 55:727–730CrossRefPubMed

12.

Megison SM, Horton JW, Chao H et al (1990) A new model for intestinal ischemia in the rat. J Surg Res 49:168–173CrossRefPubMed

13.

Bernard Y, Melchior C, Tschirhart E et al (2008) Co-cultures of human coronary smooth muscle cells and dimethyl sulfoxide-differentiated HL60 cells upregulate ProMMP9 activity and promote mobility-modulation by reactive oxygen species. Inflammation 31:287–298CrossRefPubMed

14.

Benkoe T, Reck C, Gleiss A et al (2012) Interleukin 8 correlates with intestinal involvement in surgically treated infants with necrotizing enterocolitis. J Pediatr Surg 47:1548–1554CrossRefPubMed

15.

Benkoe TM, Mechtler TP, Weninger M, Pones M, Rebhandl W, Kasper DC (2014) Serum levels of interleukin-8 and gut-associated biomarkers in diagnosing necrotizing enterocolitis in preterm infants. J Pediatr Surg 49:1446–1451CrossRefPubMed

16.

José A, Nogueira-Machadoa CMdOV (2012) HMGB-1 as a Target for Inflammation Controlling. Recent Pat Endocr Metab Immune Drug Dis 6:201–209CrossRef

17.

Hamada T, Torikai M, Kuwazuru A et al (2008) Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum 58:2675–2685CrossRefPubMed

18.

Dai S, Sodhi C, Cetin S et al (2010) Extracellular high mobility group box-1 (HMGB1) inhibits enterocyte migration via activation of Toll-like receptor-4 and increased cell-matrix adhesiveness. J Biol Chem 285:4995–5002CrossRefPubMed

19.

Zamora R, Grishin A, Wong C et al (2005) High-mobility group box 1 protein is an inflammatory mediator in necrotizing enterocolitis: protective effect of the macrophage deactivator semapimod. Am J Physiol Gastrointest Liver Physiol 289:G643–G652CrossRefPubMed

Titel: Prophylactic efficacy of enteral miconazole administration for neonatal intestinal perforation and its potential mechanism
verfasst von: Motofumi Torikai
Satoshi Ibara
Satoshi Ieiri
Takashi Hamada
Hiroyuki Noguchi
Kazunobu Sueyoshi
Takeo Fukuda
Kazuhiro Abeyama
Publikationsdatum: 29.07.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Surgery International / Ausgabe 10/2016
Print ISSN: 0179-0358
Elektronische ISSN: 1437-9813
DOI: https://doi.org/10.1007/s00383-016-3946-6

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Prophylactic efficacy of enteral miconazole administration for neonatal intestinal perforation and its potential mechanism